Literature DB >> 11312029

Liposome-mediated DNA vaccination: the effect of vesicle composition.

Y Perrie1, P M Frederik, G Gregoriadis.   

Abstract

Liposome-entrapped DNA has been shown to enhance the potency of DNA vaccines, possibly by facilitating uptake of the plasmid by antigen-presenting cells (APC). In this paper, we have investigated the influence of the liposomal composition and surface charge on such potency. Plasmid DNA pRc/CMV HBS encoding the S (small) region of hepatitis B surface antigen was entrapped within cationic liposomes of various compositions and surface charges with high efficiency (88-97% of the amount used) by the dehydration-rehydration method that generates dehydration-rehydration vesicles (DRV). Cryo-electron microscopy revealed that DNA-containing DRV (DRV(DNA)) were multilamellar. In immunisation studies, female Balb/c mice were given two to four intramuscular injections of 10 microg naked or liposome-entrapped pRc/CMV HBS and bled at time intervals. Results indicate that the lipid composition of the DRV(DNA) influences the strength of the humoural response (immunoglobulin (Ig)G subclasses) with inclusion of dioleoyl phosphatidylethanolamine (DOPE) or phosphatidylethanolamine (PE) in the liposomal structure contributing to greater responses. DRV(DNA) in which the DOPE or PE were omitted or substituted with cholesterol led to significant reduction of humoural responses against the encoded antigen. Replacing phosphatidylcholine (PC) in the DRV(DNA) with the high-melting distearoyl phosphatidylcholine also contributed to lower responses. In other experiments, IgG responses were monitored in mice immunised with pRc/CMV HBS entrapped in DRV composed of PC and DOPE as before but incorporating increasing amounts of DOTAP (1-16 micromol). Maximal IgG responses were observed at 10 weeks after the first of four injections and suggested a trend of higher responses when 4 or 8 micromol DOTAP was present in the DRV(DNA) formulation. Cell-mediated immunity (measured in terms of endogenous antigen-specific splenic interferon-gamma) in mice immunised with pRc/CMV HBS entrapped in liposomes composed of PC, DOPE and DOTAP (16:8:4 molar ratio) was much greater than in animals treated with naked plasmid. These results indicate that liposome-mediated DNA immunisation is more effective than the use of naked DNA, and also suggest that the presence of fusogenic phosphatidylethanolamine in DRV in conjunction with a low-melting phosphatidylcholine and an appropriate content of cationic lipid might contribute to more effective liposomal DNA vaccines. The notion that liposomes improve immune responses to the plasmid-encoded vaccine by facilitating the latter's uptake by APC was supported by the observation that in Balb/c mice injected intramuscularly with liposome-entrapped pCMV. Enhanced green fluorescent protein, expression of the gene in terms of fluorescence intensity in the draining lymph nodes, was much greater than in animals treated with the naked plasmid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11312029     DOI: 10.1016/s0264-410x(00)00432-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

Review 1.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

Review 4.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 5.  Liposome-nucleic acid immunotherapeutics.

Authors:  Steven Dow
Journal:  Expert Opin Drug Deliv       Date:  2008-01       Impact factor: 6.648

Review 6.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

7.  Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens.

Authors:  Yuchen Fan; Preety Sahdev; Lukasz J Ochyl; Jonathan Akerberg; James J Moon
Journal:  J Control Release       Date:  2015-04-11       Impact factor: 9.776

8.  Immunogenicity of a bovine herpesvirus 1 glycoprotein D DNA vaccine complexed with bovine neutrophil beta-defensin 3.

Authors:  Sarah Mackenzie-Dyck; Laura Latimer; Ethel Atanley; Jennifer Kovacs-Nolan; Sam Attah-Poku; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2014-11-05

9.  Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen.

Authors:  Vincent W Bramwell; Jim E Eyles; Satyanarayana Somavarapu; H Oya Alpar
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

10.  Protective effect of DNA-mediated immunization with liposome-encapsulated GRA4 against infection of Toxoplasma gondii.

Authors:  Rui Chen; Shao-Hong Lu; Qun-Bo Tong; Di Lou; Dong-Yan Shi; Bing-Bing Jia; Guo-Ping Huang; Jin-Fu Wang
Journal:  J Zhejiang Univ Sci B       Date:  2009-07       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.